FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, Gillett C, Grigoriadis A, Tutt A, Reis-Filho JS, Ashworth A.
Turner N, et al.
Cancer Res. 2010 Mar 1;70(5):2085-94. doi: 10.1158/0008-5472.CAN-09-3746. Epub 2010 Feb 23.
Cancer Res. 2010.
PMID: 20179196
Free PMC article.